Clinical Trials
213
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (131 trials with phase data)• Click on a phase to view related trials
Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage
- Conditions
- Cerebral Amyloid AngiopathyIntracerebral Hemorrhage Lobar
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT07026994
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
🇨🇳Huashan Hospital, Fudan University, Shanghai, China
CHinese ischEmic Stroke Beyond 4.5 Hours With TeNecteplase Under Optimized Non-Contrast CT Selection
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: 0.25mg/kg TNKDrug: Standard medical treatment
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 890
- Registration Number
- NCT06994975
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, China
Early Diagnosis and Recurrence Monitoring of Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2025-05-28
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 1200
- Registration Number
- NCT06991452
- Locations
- 🇨🇳
Huashan Hospital, Shanghai, Shanghai, China
Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets
- Conditions
- Hyperuricemia or GoutNephrolithiasis
- Interventions
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 312
- Registration Number
- NCT06966635
- Locations
- 🇨🇳
Huashan hospital, Fudan university, Shanghai, China
Clinical Safety and Efficacy of Flow-diverter in the Treatment of Intracranial Aneurysms
- Conditions
- Flow Diverter
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 523
- Registration Number
- NCT06943729
- Prev
- 1
- 2
- 3
- 4
- 5
- 43
- Next
News
Bio-Thera's BAT4406F Achieves Early Trial Success in Rare Neurological Disorder NMOSD
Bio-Thera Solutions' BAT4406F, an ADCC-enhanced anti-CD20 monoclonal antibody, demonstrated statistically significant efficacy in treating neuromyelitis optica spectrum disorder (NMOSD) during interim analysis of its pivotal Phase II/III trial.
Brain-Computer Interface Advances Enable Speech Synthesis and Action Control in Epilepsy Patient
A 43-year-old epilepsy patient with a brain tumor can now communicate and control actions through computer decoding of her thoughts, marking a significant BCI advancement.
Chinese BCI System Achieves Breakthrough in Language Decoding
A Chinese research team has achieved a breakthrough in brain-computer interface (BCI) technology using a domestically developed, invasive flexible BCI system.
Deep Brain Stimulation of Hippocampus Shows Promise for Treatment-Resistant Schizophrenia in New Trial
A crossover randomized controlled trial, DBS-HITS, is investigating deep brain stimulation (DBS) of the hippocampus for treatment-resistant schizophrenia.